TapewireFind a company

person · Reporting owner

Canton Barry

Disclosed activity across 1 company

Tapewire entity
27689
SEC CIK
0001882756

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Ginkgo Bioworks Holdings, Inc.DNA · Entity 553010% ownerJuly 28, 2026July 30, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Ginkgo Bioworks Holdings, Inc.

Report date July 28, 2026 · Filed July 30, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect35,736 Reported balance After 2026-07-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-07-28 · Grant · Acquired 35,736 · Balance 35,736

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect117,135 Reported balance After 2026-07-28 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-07-28 · Grant · Acquired 117,135 · Balance 117,135

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F3: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026.

Restricted Stock UnitsSEC Table II · derivative / convertible securityIndirectBy Spouse39,038 Reported balance After 2026-07-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-07-28 · Grant · Acquired 39,038 · Balance 39,038

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027.

Restricted Stock UnitsSEC Table II · derivative / convertible securityIndirectBy Spouse127,423 Reported balance After 2026-07-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-07-28 · Grant · Acquired 127,423 · Balance 127,423

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F3: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027.

F3: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 28, 2026 Filed Jul 30, 2026 20:28 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 GrantRestricted Stock Units · Derivative 127,423 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-26-051089 · wk-form4_1785443315.xml · derivative · entry 4

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 127,423

Underlying: Class A Common Stock · 127,423 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F3 · derivative.exercise_date: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026.

F3 · derivative.expiration_date: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026.

Read SEC document
July 28, 2026 Filed Jul 30, 2026 20:28 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 GrantRestricted Stock Units · Derivative 39,038 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-26-051089 · wk-form4_1785443315.xml · derivative · entry 3

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 39,038

Underlying: Class A Common Stock · 39,038 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · derivative.exercise_date: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027.

F2 · derivative.expiration_date: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027.

Read SEC document
July 28, 2026 Filed Jul 30, 2026 20:28 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 GrantRestricted Stock Units · Derivative 117,135 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-26-051089 · wk-form4_1785443315.xml · derivative · entry 2

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,135

Underlying: Class A Common Stock · 117,135 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F3 · derivative.exercise_date: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026.

F3 · derivative.expiration_date: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026.

Read SEC document
July 28, 2026 Filed Jul 30, 2026 20:28 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 GrantRestricted Stock Units · Derivative 35,736 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-26-051089 · wk-form4_1785443315.xml · derivative · entry 1

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,736

Underlying: Class A Common Stock · 35,736 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · derivative.exercise_date: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027.

F2 · derivative.expiration_date: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027.

Read SEC document
April 10, 2026 Filed Apr 13, 2026 21:00 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 124,727 $6.43 $802,493.52
Disclosure

SEC source: 0001628280-26-024929 · wk-form4_1776114037.xml · nonDerivative · entry 2

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 436,422

F2 · kind: Represents shares sold by the Reporting Person's spouse to cover tax withholding obligations in connection with the vesting of PSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person's spouse. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.

Read SEC document
April 09, 2026 Filed Apr 10, 2026 21:01 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 13,116 $6.40 $83,903.05
Disclosure

SEC source: 0001628280-26-024744 · wk-form4_1775854911.xml · nonDerivative · entry 4

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 338,568

F2 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.

Read SEC document
April 09, 2026 Filed Apr 13, 2026 21:00 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionPerformance-Based Restricted Stock Unit · Derivative 251,786 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-26-024929 · wk-form4_1776114037.xml · derivative · entry 3

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 0

Underlying: Class A Common Stock · 251,786 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F1 · kind: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F1 · price: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F3 · derivative.exercise_date: On June 19, 2025, the Reporting Person's spouse was granted 375,800 PSUs based on a company-wide cash flow reduction target over a one-year period beginning on January 1, 2025 and ending on December 31, 2025. The total number of vested PSUs distributed by Issuer on April 9, 2026 in the form of Class A Common Stock reflects actual performance equal to 67% of target performance, as certified by the Compensation Committee of the Board of Directors.

F3 · derivative.expiration_date: On June 19, 2025, the Reporting Person's spouse was granted 375,800 PSUs based on a company-wide cash flow reduction target over a one-year period beginning on January 1, 2025 and ending on December 31, 2025. The total number of vested PSUs distributed by Issuer on April 9, 2026 in the form of Class A Common Stock reflects actual performance equal to 67% of target performance, as certified by the Compensation Committee of the Board of Directors.

Read SEC document
April 09, 2026 Filed Apr 13, 2026 21:00 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass A Common Stock 251,786 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-26-024929 · wk-form4_1776114037.xml · nonDerivative · entry 1

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 561,149

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F1 · price: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Read SEC document
April 08, 2026 Filed Apr 10, 2026 21:01 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionPerformance-Based Restricted Stock Unit · Derivative 27,738 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-26-024744 · wk-form4_1775854911.xml · derivative · entry 6

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 27,738 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F1 · kind: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F1 · price: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F3 · derivative.exercise_date: On June 19, 2025, the Reporting Person was granted 82,800 PSUs based on a company-wide cash flow reduction target over a one-year period beginning on January 1, 2025 and ending on December 31, 2025. The total number of vested PSUs distributed by Issuer on April 7, 2026 and April 8, 2026 in the form of Class A Common Stock reflects actual performance equal to 67% of target performance, as certified by the Compensation Committee of the Board of Directors.

F3 · derivative.expiration_date: On June 19, 2025, the Reporting Person was granted 82,800 PSUs based on a company-wide cash flow reduction target over a one-year period beginning on January 1, 2025 and ending on December 31, 2025. The total number of vested PSUs distributed by Issuer on April 7, 2026 and April 8, 2026 in the form of Class A Common Stock reflects actual performance equal to 67% of target performance, as certified by the Compensation Committee of the Board of Directors.

Read SEC document
April 08, 2026 Filed Apr 10, 2026 21:01 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 13,155 $6.93 $91,164.15
Disclosure

SEC source: 0001628280-26-024744 · wk-form4_1775854911.xml · nonDerivative · entry 3

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 351,684

F2 · kind: Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.

Read SEC document
April 08, 2026 Filed Apr 10, 2026 21:01 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass A Common Stock 27,738 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-26-024744 · wk-form4_1775854911.xml · nonDerivative · entry 2

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 364,839

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F1 · price: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Read SEC document
April 07, 2026 Filed Apr 10, 2026 21:01 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionPerformance-Based Restricted Stock Unit · Derivative 27,738 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-26-024744 · wk-form4_1775854911.xml · derivative · entry 5

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,738

Underlying: Class A Common Stock · 27,738 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F1 · kind: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F1 · price: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F3 · derivative.exercise_date: On June 19, 2025, the Reporting Person was granted 82,800 PSUs based on a company-wide cash flow reduction target over a one-year period beginning on January 1, 2025 and ending on December 31, 2025. The total number of vested PSUs distributed by Issuer on April 7, 2026 and April 8, 2026 in the form of Class A Common Stock reflects actual performance equal to 67% of target performance, as certified by the Compensation Committee of the Board of Directors.

F3 · derivative.expiration_date: On June 19, 2025, the Reporting Person was granted 82,800 PSUs based on a company-wide cash flow reduction target over a one-year period beginning on January 1, 2025 and ending on December 31, 2025. The total number of vested PSUs distributed by Issuer on April 7, 2026 and April 8, 2026 in the form of Class A Common Stock reflects actual performance equal to 67% of target performance, as certified by the Compensation Committee of the Board of Directors.

Read SEC document
April 07, 2026 Filed Apr 10, 2026 21:01 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 Exercise / conversionClass A Common Stock 27,738 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-26-024744 · wk-form4_1775854911.xml · nonDerivative · entry 1

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 337,101

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F1 · price: Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Read SEC document
April 25, 2024 Filed Apr 29, 2024 20:53 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 GrantStock Option · Derivative 5,000,000 $0.00 Strike: $2.50 $0.00
Disclosure

SEC source: 0001127602-24-013570 · form4.xml · derivative · entry 2

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 5,000,000

Underlying: Class A Common Stock · 5,000,000 shares

Expires 2034-04-25

F1 · derivative.exercise_date: The options are subject both to time-based and performance-based vesting criteria (the "Founder Options"). The performance-based vesting is tied to the achievement of four specified stock price hurdles within a five-year period, with 10% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $5.00, 10% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $7.50, 20% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $10.00 and the remaining 60% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $12.50. If any of the performance-based criteria are achieved during the five-year performance period, the awards will vest on the five-year anniversary of the grant date, subject to the Reporting Person's or spouse's continued employment with Ginkgo on such anniversary.

Read SEC document
April 25, 2024 Filed Apr 29, 2024 20:53 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 GrantStock Option · Derivative 5,000,000 $0.00 Strike: $2.50 $0.00
Disclosure

SEC source: 0001127602-24-013570 · form4.xml · derivative · entry 1

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000,000

Underlying: Class A Common Stock · 5,000,000 shares

Expires 2034-04-25

F1 · derivative.exercise_date: The options are subject both to time-based and performance-based vesting criteria (the "Founder Options"). The performance-based vesting is tied to the achievement of four specified stock price hurdles within a five-year period, with 10% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $5.00, 10% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $7.50, 20% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $10.00 and the remaining 60% of the Founder Options vesting based on the achievement of a 90-calendar-day average stock price of $12.50. If any of the performance-based criteria are achieved during the five-year performance period, the awards will vest on the five-year anniversary of the grant date, subject to the Reporting Person's or spouse's continued employment with Ginkgo on such anniversary.

Read SEC document
December 21, 2023 Filed Dec 22, 2023 21:59 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.74 $65,398.05
Disclosure

SEC source: 0001127602-23-030397 · form4.xml · nonDerivative · entry 2

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,374,544

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 to $1.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
December 20, 2023 Filed Dec 22, 2023 21:59 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.80 $67,581.75
Disclosure

SEC source: 0001127602-23-030397 · form4.xml · nonDerivative · entry 1

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 12,374,554

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
December 14, 2023 Filed Dec 15, 2023 22:07 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.63 $61,256.55
Disclosure

SEC source: 0001127602-23-029727 · form4.xml · nonDerivative · entry 3

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,412,194

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.48 to $1.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
December 14, 2023 Filed Dec 15, 2023 22:07 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 821 $1.48 $1,215.08
Disclosure

SEC source: 0001127602-23-029727 · form4.xml · nonDerivative · entry 2

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 12,412,204

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

Read SEC document
December 13, 2023 Filed Dec 15, 2023 22:07 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 36,829 $1.34 $49,350.86
Disclosure

SEC source: 0001127602-23-029727 · form4.xml · nonDerivative · entry 1

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 12,413,025

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.285 to $1.445, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
December 12, 2023 Filed Dec 12, 2023 22:06 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 GiftClass A Common Stock 200,000 $0.00 $0.00
Disclosure

SEC source: 0001127602-23-029444 · form4.xml · nonDerivative · entry 2

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,449,844

F1 · kind: The transactions being reported herein relate to a charitable donation of shares of Class A Common Stock.

Read SEC document
December 08, 2023 Filed Dec 12, 2023 22:06 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 ConversionClass B Common Stock · Derivative 200,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-029444 · form4.xml · derivative · entry 4

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bartholomew Canton Living Trust

Disclosed balance after: 69,989,783

Underlying: Class A Common Stock · 200,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F2 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

F2 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

Read SEC document
December 08, 2023 Filed Dec 12, 2023 22:06 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 ConversionClass A Common Stock 200,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-23-029444 · form4.xml · nonDerivative · entry 1

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,649,844

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions being reported herein relate to a charitable donation of shares of Class A Common Stock.

F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

Read SEC document
December 07, 2023 Filed Dec 8, 2023 22:17 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.32 $49,509.75
Disclosure

SEC source: 0001127602-23-029168 · form4.xml · nonDerivative · entry 2

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,449,844

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.29 to $1.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
December 06, 2023 Filed Dec 8, 2023 22:17 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.32 $49,810.95
Disclosure

SEC source: 0001127602-23-029168 · form4.xml · nonDerivative · entry 1

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 12,449,854

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.285 to $1.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
November 30, 2023 Filed Dec 1, 2023 21:54 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.35 $50,940.45
Disclosure

SEC source: 0001127602-23-028612 · form4.xml · nonDerivative · entry 2

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,487,494

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.29 to $1.415, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
November 29, 2023 Filed Dec 1, 2023 21:54 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.45 $54,592.50
Disclosure

SEC source: 0001127602-23-028612 · form4.xml · nonDerivative · entry 1

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 12,487,504

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.39 to $1.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
November 24, 2023 Filed Nov 27, 2023 22:00 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.42 $53,274.75
Disclosure

SEC source: 0001127602-23-028309 · form4.xml · nonDerivative · entry 2

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,525,144

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.375 to $1.455, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
November 22, 2023 Filed Nov 27, 2023 22:00 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.40 $52,785.30
Disclosure

SEC source: 0001127602-23-028309 · form4.xml · nonDerivative · entry 1

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 12,525,154

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.37 to $1.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
November 16, 2023 Filed Nov 17, 2023 21:59 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.45 $54,705.45
Disclosure

SEC source: 0001127602-23-027860 · form4.xml · nonDerivative · entry 2

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,562,794

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.405 to $1.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
November 15, 2023 Filed Nov 17, 2023 21:59 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.54 $58,131.60
Disclosure

SEC source: 0001127602-23-027860 · form4.xml · nonDerivative · entry 1

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 12,562,804

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.44 to $1.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
November 09, 2023 Filed Nov 13, 2023 13:00 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.29 $48,530.85
Disclosure

SEC source: 0001127602-23-027139 · form4.xml · nonDerivative · entry 2

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,600,444

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.26 to $1.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 13:00 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.50 $56,625.60
Disclosure

SEC source: 0001127602-23-027139 · form4.xml · nonDerivative · entry 1

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 12,600,454

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.485 to $1.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
November 02, 2023 Filed Nov 3, 2023 21:04 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.52 $57,077.40
Disclosure

SEC source: 0001127602-23-026779 · form4.xml · nonDerivative · entry 2

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,638,094

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.40 to $1.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
November 01, 2023 Filed Nov 3, 2023 21:04 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.34 $50,563.95
Disclosure

SEC source: 0001127602-23-026779 · form4.xml · nonDerivative · entry 1

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 12,638,104

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.32 to $1.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
October 26, 2023 Filed Oct 27, 2023 20:50 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.46 $54,931.35
Disclosure

SEC source: 0001127602-23-026329 · form4.xml · nonDerivative · entry 2

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,675,744

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.435 to $1.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
October 25, 2023 Filed Oct 27, 2023 20:50 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.48 $55,609.05
Disclosure

SEC source: 0001127602-23-026329 · form4.xml · nonDerivative · entry 1

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 12,675,754

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.415 to $1.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
October 19, 2023 Filed Oct 20, 2023 20:58 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.61 $60,503.55
Disclosure

SEC source: 0001127602-23-026121 · form4.xml · nonDerivative · entry 2

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,713,394

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.55 to $1.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
October 18, 2023 Filed Oct 20, 2023 20:58 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.69 $63,628.50
Disclosure

SEC source: 0001127602-23-026121 · form4.xml · nonDerivative · entry 1

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 12,713,404

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.65 to $1.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
October 12, 2023 Filed Oct 13, 2023 20:59 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.66 $62,386.05
Disclosure

SEC source: 0001127602-23-025842 · form4.xml · nonDerivative · entry 2

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,751,044

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.61 to $1.735, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
October 11, 2023 Filed Oct 13, 2023 20:59 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.76 $66,113.40
Disclosure

SEC source: 0001127602-23-025842 · form4.xml · nonDerivative · entry 1

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 12,751,054

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.715 to $1.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
October 05, 2023 Filed Oct 6, 2023 21:05 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.67 $62,800.20
Disclosure

SEC source: 0001127602-23-025687 · form4.xml · nonDerivative · entry 2

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,788,694

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.615 to $1.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
October 04, 2023 Filed Oct 6, 2023 21:05 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.62 $60,842.40
Disclosure

SEC source: 0001127602-23-025687 · form4.xml · nonDerivative · entry 1

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 12,788,704

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.56 to $1.655, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
September 28, 2023 Filed Sep 29, 2023 20:54 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.75 $65,887.50
Disclosure

SEC source: 0001127602-23-024877 · form4.xml · nonDerivative · entry 2

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,826,344

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.71 to $1.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
September 27, 2023 Filed Sep 29, 2023 20:54 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.83 $68,899.50
Disclosure

SEC source: 0001127602-23-024877 · form4.xml · nonDerivative · entry 1

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 12,826,354

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $2.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
September 21, 2023 Filed Sep 22, 2023 20:59 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.77 $66,452.25
Disclosure

SEC source: 0001127602-23-024676 · form4.xml · nonDerivative · entry 2

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,863,994

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
September 20, 2023 Filed Sep 22, 2023 20:59 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $1.84 $69,238.35
Disclosure

SEC source: 0001127602-23-024676 · form4.xml · nonDerivative · entry 1

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 12,864,004

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.81 to $1.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
September 14, 2023 Filed Sep 15, 2023 20:56 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $2.00 $75,149.40
Disclosure

SEC source: 0001127602-23-024233 · form4.xml · nonDerivative · entry 2

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,901,644

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.95 to $2.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
September 13, 2023 Filed Sep 15, 2023 20:56 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $2.04 $76,918.95
Disclosure

SEC source: 0001127602-23-024233 · form4.xml · nonDerivative · entry 1

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 12,901,654

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.02 to $2.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document
September 07, 2023 Filed Sep 8, 2023 20:52 UTC Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 SaleClass A Common Stock 37,650 $2.13 $80,232.15
Disclosure

SEC source: 0001127602-23-023912 · form4.xml · nonDerivative · entry 2

Canton Barry · CIK 0001882756 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,939,294

F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person or the Reporting Person's spouse and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.095 to $2.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.